Redwood Pharma AB (publ.)

📍 Stockholm, Sweden🗓 Founded 2012👥 2 employees💰 Last funded Jun 2023
Medical Practices🌐 redwoodpharma.se
Website LinkedIn
Redwood Pharma develops ophthalmic drugs in areas where medical need is especially great. This is an approach exemplified by our very first project. RP101 treats chronic dry eyes in post-menopausal women. Something that is possible thanks to our drug delivery platform IntelliGel, which controls the release of active substances. The platform also supports improved dosages of other established drugs. Dry eye disease (DED) offers enormous potential. A total of some 344 million people are affected, equivalent to a global market of USD 3.1 billion. And the market is expected to grow, not least due to the lack of effective treatments. This is something we want to change. Our strategy is to sign licence agreements with drug companies that will manufacture and market products on the global market. Redwood Pharma AB (publ.) is listed on the Nasdaq First North Growth Market (ticker: REDW, ISIN: SE008294789).
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2012
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Sweden
1
Frequently asked questions
Who invested in Redwood Pharma AB (publ.)?
Redwood Pharma AB (publ.) has 1 investors on record on gritt.io.
When did Redwood Pharma AB (publ.) last raise funding?
The most recent investment in Redwood Pharma AB (publ.) recorded on gritt.io was in June 2023.
When was Redwood Pharma AB (publ.) founded?
Redwood Pharma AB (publ.) was founded in 2012.
What industry is Redwood Pharma AB (publ.) in?
Redwood Pharma AB (publ.) operates in Medical Practices. Find similar Medical Practices investors on gritt.io.
Where is Redwood Pharma AB (publ.) based?
Redwood Pharma AB (publ.) is headquartered in Stockholm, Sweden.